JARID1B’s tumor-promoting function is perhaps best characterized in breast cancer, where it is a bona fide oncogene that is amplified and overexpressed in some hormone receptor-positive tumors and drives a luminal-type gene expression profile [4, 9]. This evidence concerns the gene NR4A1 and breast carcinoma.